Astrazeneca (AZN) Inventory (2009 - 2026)

Astrazeneca's Inventory history runs 18 years deep, the most recent figure standing at $6.6 billion for Q1 2026.

• In Q1 2026, Inventory rose 11.66% year-over-year to $6.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 11.66% YoY), while the FY2025 annual figure was $6.6 billion, up 24.0% from the prior year.
• Inventory was $6.6 billion for Q1 2026 at Astrazeneca, roughly flat from $6.6 billion in the prior quarter.
• In the past five years, Inventory ranged from a high of $7.6 billion in Q1 2022 to a low of $4.7 billion in Q4 2022.
• Historically, Inventory has averaged $5.8 billion across 5 years, with a median of $5.7 billion in 2024.
• Biggest YoY gain for Inventory was 125.56% in 2022; the steepest drop was 51.77% in 2022.
• A 5-year view of Inventory shows it stood at $4.7 billion in 2022, then grew by 15.43% to $5.4 billion in 2023, then declined by 2.51% to $5.3 billion in 2024, then increased by 24.0% to $6.6 billion in 2025, then advanced by 0.2% to $6.6 billion in 2026.
• The last three Inventory figures came in at $6.6 billion (Q1 2026), $6.6 billion (Q4 2025), and $6.6 billion (Q3 2025), per Business Quant data.